CRISPR gene-editing approved for first human trials
A federal ethics and biosafety panel has approved the first ever human trials of the CRISPR-Cas9 gene editing technique. Researchers from the University of Pennsylvania aim to modify the immune system “T cells” in patients, helping them better fight off several kinds of cancer. The work will be funded by the Parker Institute for Cancer Immunotherapy, foundedearlier this year by tech billionaire Sean Parker. While the federal ethics panel nod was a big hurdle, researchers still need approval from the FDA and the hospitals conducting the studies before they can start.